Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing

With the US Food and Drug Administration (FDA) approval of four CD19- and one BCMA-targeted chimeric antigen receptor (CAR) therapy for B cell malignancies, CAR T cell therapy has finally reached the status of a medicinal product. The successful manufacturing of autologous CAR T cell products is a k...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiuyan, Borquez-Ojeda, Oriana, Stefanski, Jolanta, Du, Fang, Qu, Jinrong, Chaudhari, Jagrutiben, Thummar, Keyur, Zhu, Mingzhu, Shen, Ling-bo, Hall, Melanie, Gautam, Paridhi, Wang, Yongzeng, Sénéchal, Brigitte, Sikder, Devanjan, Adusumilli, Prasad S., Brentjens, Renier J., Curran, Kevin, Geyer, Mark B., Mailankhody, Sham, O’Cearbhaill, Roisin, Park, Jae H., Sauter, Craig, Slovin, Susan, Smith, Eric L., Rivière, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411225/
https://www.ncbi.nlm.nih.gov/pubmed/34514029
http://dx.doi.org/10.1016/j.omtm.2021.06.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411225/
https://www.ncbi.nlm.nih.gov/pubmed/34514029
http://dx.doi.org/10.1016/j.omtm.2021.06.014

Ejemplares similares